A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B

Journal of Viral Hepatitis

Volumn 14, Issue 2, 2007, Pages 75-88

  Takeda, A ^a   Jones, J ^a   Shepherd, J ^a   Davidson, P ^a   Price, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adefovir dipivoxil; Cost effectiveness; Economic evaluation; Hepatitis B; Pegylated interferon alpha; Systematic review

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2A INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; TENOFOVIR; VIRUS DNA;

ALOPECIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FATIGUE; FEVER; FOLLOW UP; HEALTH CARE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIFE EXPECTANCY; MEDLINE; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADENINE; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; ENGLAND; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS; WALES;

EID: 33846434815     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00808.x     Document Type: Review

References (49)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362(9401): 2089-2094.
2. Department of Health. Getting Ahead of the Curve: a Strategy for Combating Infectious Diseases (including other aspects of health protection). London: HMSO, 2002.
3. Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy. J Clin Virol 2004; 29: (4): 211-220.
4. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 3(6): 687-696.
5. NHS Centre for Reviews and DisseminationUndertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for those Carrying Out or Commissioning Reviews. York: York Publishing Services Ltd, 2001; Report No.: CRD Report Number 4 (2nd edn).
6. Egger M, Davey Smith G. Systematic Reviews in Health Care, 2nd ed. London: BMJ Books, 2001.
7. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon-alfa-2a for the treatment of chronic hepatitis B - a systematic review and economic evaluation. Health Technol Assess 2006; 10(28): 200.
8. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10(4): 298-305.
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348(9): 800-807.
10. Lau GKK, Piratvisuth T, Luo KX et al. Peginterferon-alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 2682-2695.
11. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348(9): 808-816.
12. Marcellin P, Lau GK, Bonino F et al. Peginterferon-alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351(12): 1206-1217.
13. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126(1): 81-90.
14. Peters MG, Hann HH, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126(1): 91-101.
15. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63(20): 2215-2234.
16. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005; 22(6): 519-528.
17. Hadziyannis S, Tassopolous N, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352(26): 2673-2681.
18. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142(10): 821-831.
19. Buti M, Casado MA, Calleja JL et al. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2006; 23(3): 409-419.
20. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122(9): 664-675.
21. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon-alfa: an economic appraisal. Hepatology 1995; 22(6): 1863-1873.
22. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127(10): 855-865.
23. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17(5): 409-427.
24. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 2001; 7(7): 677-682.
25. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17(2): 153-164.
26. Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002; 5(5): 404-420.
27. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27(1): 209-212.
28. Pojoga C, Dumitrascu DL, Pascu O, Grigorescu M, Radu C, Damian D. Impaired health-related quality of life in Romanian patients with chronic viral hepatitis before antiviral therapy. Eur J Gastroenterol Hepatol 2004; 16(1): 27-31.
29. Kind P. Population Norms for EQ-5D. York: Centre for Health Economics, University of York, 1999; CHE Discussion Paper 172.
30. Wright M, Grieve R, Roberts JA, Main J, Thomas HC. Health Benefits of Anti-viral Therapy for Mild Chronic Hepatitis C. health : Technol Assess, 2006; 10(21) pp. 130.
31. Ratcliffe J, Longworth L, Young T et al. Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study. Liver Transpl 2002; 8(3): 263-270.
32. Owens DK. In the eye of the beholder: assessment of health-related quality of life. Hepatology 1998; 27(1): 292-293.
33. Chang TT, Shiffman M, Tong M et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) J Hepatol 2004; 40: 424.
34. Hadziyannis S, Tassopoulos N, Chang TT et al. Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES). J Hepatol 2004; 40: 46.
35. Marcellin P, Chang TT, Lim S et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg plus chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. Hepatology 2004; 40(4 Suppl. 1): 655A.
36. Xiong S, Yang H, Westland CE et al. Resistance surveillance of HBeAg-chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). J Hepatol 2003; 38: 628.
37. Sung JJY, Lai JY, Zeuzem S et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38(Suppl. 2): 25-26.
38. De Franchis R, Hadengue A, Lau G et al. EASL international consensus conference on hepatitis B 13-14 September, 2002 Geneva, Switzerland Consensus statement (Long version). J Hepatol 2003; 39(Suppl. 1): S3-S25.
39. Wong D, Cheung A, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119(4): 312-323.
40. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8(3): 493-496.
41. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32(3): 294-298.
42. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988; 108(3): 390-401.
43. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11(2): 97-107.
44. Lau DT, Everhart J, Kleiner DL. Long-term follow-up of patients with chronic hepatitis B treated with interferonalfa. Gastroenterology 1997; 113(5): 1660-1667.
45. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review. Health Technol Assess 2004; Vol 8,no. 39, pp 140.
46. Lok ASF, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125(6): 1714-1722.
47. Locarnini S, Qi X, Arterburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42(Suppl. 2): 17.
48. Hadziyannis S, Tassopolous N, Chang TT et al. Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg-chronic hepatitis B (CHB) patients. J Hepatol 2005; 42(Suppl. 2): 178.
49. Longworth L, Young T, Ratcliffe J, Bryan S, Buxton M. Economic Evaluation of the Transplantation Programme in England and Wales: an Assessment of the Costs of Liver Transplantation. Unpublished Report to the Department of Health, 2001.